Clinical Trials Logo

Filter by:
NCT ID: NCT06238011 Not yet recruiting - CABG Clinical Trials

Dexmedetomidine vs Control on Attenuation Hemodynamic Response to Noxious Stimuli in CABG Surgical Patients

CABG
Start date: February 28, 2024
Phase: N/A
Study type: Interventional

Aim to study efficacy of dexmedetomidine to attenuate hemodynamic response to intubation, skin incision, sternotomy and aortic cannulation

NCT ID: NCT06229951 Not yet recruiting - Clinical trials for Osteo Arthritis Knee

Hydrolyzed Collagen and Undenatured Collagen Type II in OA Knee

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

Randomized controlled trial Targeted patients who come to receive treatment for osteoarthritis that meets the research indications will be assigned to a random group by the box of 4 randomization method, with a sequence that is randomly generated by a computer. The groups are divided into two groups: Group 1: Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen Group 2: Control patients will take placebo Primary outcome : Pain level

NCT ID: NCT06226532 Not yet recruiting - Intubation Clinical Trials

Effect of Lidocaine Sprayed for Attenuating Hemodynamic Response During Laryngoscopy and Intubation

Start date: January 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to to evaluate the efficacy of lidocaine sprayed at the laryngeal inlet combined with the endotracheal tube cuff compare with intravenous lidocaine on the hemodynamic response to laryngoscopy and intubation in patients undergoing elective neurological procedures during general anesthesia with total intravenous technique. The main question it aims to answer is: - Does topical lidocaine sprayed at the laryngeal inlet combined with the endotracheal tube cuff have more effect on stabilizing hemodynamic responses to laryngoscopy and intubation than intravenous lidocaine, in neurosurgical patients who undergo general anesthesia with total intravenous technique? Participants will be recruited and randomized to receive either lidocaine spray (Group SL) or intravenous lidocaine (group IL) to blunt hemodynamic response to laryngoscopy and intubation.

NCT ID: NCT06218680 Not yet recruiting - Emergence Agitation Clinical Trials

Efficacy of Low Dose Propofol Given at the End of Sevoflurane Anesthesia for Prevention of Emergence Agitation in Pediatric Patient Undergoing MRI Scan

Start date: January 20, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare Efficacy of low dose propofol(0.5 mg/kg) vs placebo given at the end of sevoflurane anesthesia for prevention of emergence agitation in pediatric patient undergoing MRI scan. The main question it aims to answer is "Can low dose propofol reduce the incidence of emergence agitation after general anesthesia?" Participants will be given propofol 0.5 mg/kg or saline according to the allocated group at the completion of MRI scan

NCT ID: NCT06217939 Not yet recruiting - Shock, Septic Clinical Trials

Early Intravenous Hydrocortisone in Sepsis

Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare two timings of steroid treatment in patients with severe infection who develop low blood pressure. The main question it aims to answer is: • Which timing strategy is better between starting steroid treatment very early in the course of severe infection, or waiting until the patient does not respond to medicine that raises blood pressure according to the current guidelines? Participants will receive either early steroid treatment or placebo right after they develop low blood pressure from infection. Both participants and treating doctors will not know which treatment participants received. When blood pressure goal is not reached after a moderate dose of drugs that raise blood pressure, an open-label steroid treatment will be given to participants as indicated in the current guidelines.

NCT ID: NCT06207045 Not yet recruiting - Gout Flare Clinical Trials

The Effects of Limb Elevation During Gout Flare Episodes

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this open-label randomized controlled trial is to explore the benefit of limb elevation in inpatient gout flare episodes, compared with standard treatment The main questions are; - Is limb elevation able to reduce pain during gout flare episodes to a greater degree compared with standard treatment ? - Is Is limb elevation able to reduce joint swelling during gout flare episodes to a greater degree compared with standard treatment ? Participants will be divided into 2 group; 1. Limb elevation group 2. control group All participants will receive standard medical therapy consisting of colchicine 0.6 mg per day plus prednisolone 30 mg per day for 2 days Pain score and joint circumference will be recored at recruitment, 24 hour and 48 hour

NCT ID: NCT06203366 Not yet recruiting - Cerebral Palsy Clinical Trials

Effect of Vojta Therapy on Upper Extremity Function of Children With Cerebral Palsy

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot study is to study the effect of Vojta therpy on upper extremity function in children with cerebral palsy. The main questions are: - to study the effect of Vojta therapy on upper extremity function in children with cerebral palsy in terms of range of motion and function - to study the effect of Vojta therapy on upper extremity function in children with cerebral palsy in terms of motion analysis while perform function

NCT ID: NCT06201533 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Low-intensity Physical-cognitive Exercise and Cognitive Function

Start date: April 2024
Phase: N/A
Study type: Interventional

This study aims to examine the effects of low-intensity, combined physical-cognitive exercise on cognitive function of older people with mild cognitive impairment (MCI) and identify the mechanisms by which this exercise protocol exerts cognitive function. Older adults with MCI will be recruited to either an exercise or a control group. Low-intensity, combined physical-cognitive exercise will be prescribed to the exercise group 3 times per week for 3 months while the control group will maintain their routine lifestyle. It is hypothesized that at the end of the trial, participants in the exercise group will demonstrate significant improvement in cognitive performance and circulating biomarkers compared to baseline and the control group.

NCT ID: NCT06196853 Not yet recruiting - Acute Kidney Injury Clinical Trials

Prevention of Cisplatin-induced Nephrotoxicity

Start date: April 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The research design is a prospective, randomized, controlled clinical trial in children to study effect of aminophylline in preserving renal function in oncologic patient received cisplatin either combined with other CMT or used alone. The participants in both groups will receive standard protocol pre-cisplatin infusion which include hydration with 5%DNSS/2 with KCL and MgSO4 IV infusion. In the treatment group, the participants will receive aminophylline infusion in the first 24 hours along with cisplatin, followed by oral aminophylline oral three times daily orally for 4 consecutive days post cisplatin. The aminophylline serum level will be maintained at the therapeutic range 10-20 mg. The side effect of aminophylline including nausea, vomiting and ECG will be monitored. The collected data including urine volume, GFR (estimated by cystatin C-creatinine based equation and by radiopharmaceutical-Tc DTPA), and renal tubular biomarker (urine B2 macroglobulin and urine NGAL) will be collected at baseline before receiving cisplatin, 24 hours and 5 days post cisplatin.

NCT ID: NCT06193187 Not yet recruiting - Healthy Volunteers Clinical Trials

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Start date: January 2024
Phase: Phase 1
Study type: Interventional

To evaluate the bioequivalence between two formulations of sacubitril/valsartan 24 mg/26 mg film-coated tablets, Entresto 50 mg (Reference) and Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg (Test), after a single oral dose administration in healthy Thai subjects under fasting conditions.